These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


363 related items for PubMed ID: 19257821

  • 1. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.
    J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA, Peacock M.
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [Abstract] [Full Text] [Related]

  • 5. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
    Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD.
    Lancet; 2013 Oct 26; 382(9902):1424-32. PubMed ID: 23927913
    [Abstract] [Full Text] [Related]

  • 6. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.
    Bone; 2006 Jan 26; 38(1):13-20. PubMed ID: 16162424
    [Abstract] [Full Text] [Related]

  • 7. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS, Glorieux FH, Rauch F.
    Calcif Tissue Int; 2009 Mar 26; 84(3):203-9. PubMed ID: 19137231
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG, Sod E, Johnson T, Chines A.
    Calcif Tissue Int; 2004 Dec 26; 75(6):469-76. PubMed ID: 15478000
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A, Bouzid K, Sahli H, Sallami S, Abdelmoula J.
    Tunis Med; 2009 Jun 26; 87(6):380-1. PubMed ID: 19927782
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb 26; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH.
    J Clin Endocrinol Metab; 2011 Feb 26; 96(2):355-64. PubMed ID: 21106710
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S.
    J Bone Miner Res; 2005 May 26; 20(5):758-63. PubMed ID: 15824848
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.